Literature DB >> 33405435

Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg).

Olga P Nyssen1, Dino Vaira2, Bojan Tepes3, Limas Kupcinskas4, Dmitry Bordin5, Ángeles Pérez-Aisa6, Antonio Gasbarrini7, Manuel Castro-Fernández8, Luis Bujanda9, Ana Garre1, Alfredo Lucendo10, Liudmila Vologzhanina11, Natasa B Jurecic12, Luis Rodrigo-Sáez13, Jose M Huguet14, Irina Voynovan5, Jorge Perez-Lasala15, Pilar Mata Romero16, Miroslav Vujasinovic17, Rustam Abdulkhakov18, Jesús Barrio19, Luis Fernandez-Salazar20, Francis Mégraud21, Colm O'Morain22, Javier P Gisbert1.   

Abstract

BACKGROUND: Managing Helicobacter pylori infection requires constant decision making, and each decision is open to possible errors. AIM: The aim was to evaluate common mistakes in the eradication of H. pylori, based on the "European Registry on Helicobacter pylori management".
METHODS: European Registry on Helicobacter pylori management is an international multicentre prospective noninterventional registry evaluating the decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice.
RESULTS: Countries recruiting more than 1000 patients were included (26,340 patients). The most common mistakes (percentages) were: (1) To use the standard triple therapy where it is ineffective (46%). (2) To prescribe eradication therapy for only 7 to 10 days (69%). (3) To use a low dose of proton pump inhibitors (48%). (4) In patients allergic to penicillin, to prescribe always a triple therapy with clarithromycin and metronidazole (38%). (5) To repeat certain antibiotics after eradication failure (>15%). (6) Failing to consider the importance of compliance with treatment (2%). (7) Not to check the eradication success (6%). Time-trend analyses showed progressive greater compliance with current clinical guidelines.
CONCLUSION: The management of H. pylori infection by some European gastroenterologists is heterogeneous, frequently suboptimal and discrepant with current recommendations. Clinical practice is constantly adapting to updated recommendations, although this shift is delayed and slow.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 33405435     DOI: 10.1097/MCG.0000000000001482

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland.

Authors:  Justyna Wasielica-Berger; Patryk Gugnacki; Maryla Mlynarczyk; Pawel Rogalski; Agnieszka Swidnicka-Siergiejko; Stefania Antonowicz; Michalina Krzyzak; Dominik Maslach; Andrzej Dabrowski; Jaroslaw Daniluk
Journal:  Int J Environ Res Public Health       Date:  2022-06-06       Impact factor: 4.614

2.  Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010-2019.

Authors:  Inés Ariño Pérez; Samuel J Martínez-Domínguez; Enrique Alfaro Almajano; Patricia Carrera-Lasfuentes; Ángel Lanas
Journal:  Antibiotics (Basel)       Date:  2022-05-20

3.  Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.

Authors:  Olga P Nyssen; Marta Espada; Javier P Gisbert
Journal:  Front Microbiol       Date:  2022-06-14       Impact factor: 6.064

4.  Treatment regimens used in the management of Helicobacter pylori in Colombia.

Authors:  Luis Fernando Valladales-Restrepo; Yessenia Correa-Sánchez; Brayan Stiven Aristizábal-Carmona; Jorge Enrique Machado-Alba
Journal:  Braz J Infect Dis       Date:  2022-02-16       Impact factor: 3.257

Review 5.  Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection.

Authors:  Malek Shatila; Anusha Shirwaikar Thomas
Journal:  J Clin Med       Date:  2022-08-30       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.